Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
South Australian bakery appoints new CEO
Vili’s Family Bakery has appointed a new CEO to lead its next phase of growth and expansion...
Champions at the 2025 Melbourne Royal Australian Food Awards
The best dairy, smallgoods, meat and preserves have been crowned at the 2025 Melbourne Royal...
IFF trend research: What makes India's Gen Alpha hungry?
IFF's latest research explores how India's youngest generation is reshaping the way we...
